Compuware ThruPut Manager Empowers Next-Generation IT Staff to Optimize Mainframe Batch Execution
New Visually Intuitive Insight into Workload Scheduling Helps Enterprises Ensure Performance of Critical Back-End Systems While Controlling Costs
- Enterprises must ensure that critical mainframe batch workloads 1) are completed on time, 2) stay within cost parameters and 3) don't interfere with real-time processing that supports digital customer engagement.
- Batch management can be jeopardized as mainframe responsibilities are transferred to a new generation of IT staff with far less platform experience, and as mainframe environments become increasingly complex.
- ThruPut Manager and its new web interface address these core operational issues by providing IT staff with intuitive, actionable insight into how batch jobs are being initiated and executed, as well as their impact on cost.
DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today released a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.
By implementing ThruPut Manager, enterprises can better safeguard performance of both batch and non-batch applications, while avoiding the significant adverse economic impact of preventable spikes in utilization as measured by Rolling 4-Hour Averages (R4HA), the metric upon which IBM bases its software licensing fees.
Additionally, with ThruPut Manager, enterprises can successfully transfer batch management responsibilities to a new generation of IT staff with far less hands-on platform experience-without exposing themselves to related risks such as missed batch execution deadlines, missed service level agreements and excess costs.
Safeguarding performance, controlling costs and smooth ownership transfers are more critical than ever given the growing importance of mainframe systems. According to a commissioned study conducted by Forrester Consulting on behalf of Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. And that percentage is expected to increase to 64 percent by 2019. The complete Forrester Opportunity Snapshot report, entitled "Modern Mainframe KPIs Are Key To A Successful Digital Strategy," can be found here.
Batch processing on the mainframe remains critical for many core business functions, such as reconciliation of financial transactions and re-pricing of mutual funds. In many cases, these batch workloads must be completed within a tight time-window. So as the size of a batch workload increases-and as other processing activity consumes an enterprise's finite platform resources-ops staff must take appropriate action. Those actions can include juggling the prioritization of jobs, assigning jobs to alternative LPARs and addressing data dependencies that may be holding up job initiation.
ThruPut Manager empowers IT staff to achieve these operational objectives by:
- Making it easy to see whether batch jobs are meeting key service metrics-especially how quickly they start executing-and if not, what underlying issues are causing delays or non-initiation.
- Graphically visualizing how it may be constraining less important workloads to minimize a R4HA peak.
- Enabling operators to avoid unnecessary R4HA peaks by adaptively shifting workload priorities while still fulfilling business imperatives-rather than limiting them to inflexible "hard-capping."
- Empowering mainframe ops teams to configure automation rules for initiating batch jobs based on parameters such as business impact, completion windows and workload size.
ThruPut Manager also helps ops teams avoid having too many batch jobs execute at the same time, commonly referred to as "over-initiating," which can cause them to compete for scarce CPU cycles-resulting in extended batch elapsed times and missed schedules, as can happen with IBM's WLM-managed initiators.
"Managing the system utilization and the user's expectations has been a real challenge for us," said Christopher Prenatt, who is the Lead Performance Engineer at Verizon. "The new ThruPut Manager GUI will give us the ability to visualize our batch workload for the first time. We can quickly see how long jobs are sitting in the queue and, if there is a problem, rapidly drill down to what the root cause may be. This will be a great addition for our application teams and ultimately help us get maximum value out of our mainframe."
"As mainframe workloads continue to increase, enterprise IT faces growing challenges in batch execution management," said Rich Ptak of IT analyst firm Ptak Associates. "Compuware ThruPut Manager provides much needed clarity and insight to fine-tune batch execution for optimal value easing budget stresses-even as less-experienced staff take on more mainframe responsibilities."
Compuware today also announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. zAdviser measures application quality, development velocity, and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts.
Today's announcements mark the 14th consecutive quarter that Compuware has announced significant innovation in the modernization and mainstreaming of the mainframe. This innovation is of vital importance to large enterprises that must get maximum business value from their mainframe environments-which are doing double-duty as both self-contained core systems of record, and as powerful back-end data and transaction processing systems for front-end customer-facing web and mobile applications.
"Enterprise CIOs have come to realize that high-cost, high-risk attempts to re-platform their supremely valuable mainframe applications make no sense. The less costly, less risky and higher return strategy is to simply adopt better technology for modernizing on platform and mainstreaming mainframe development, operations and security," said Chris O'Malley, CEO of Compuware. "Compuware is redefining what mainframe modernization means and is committed to delivering what customers need to enable them to adopt the smarter strategy."
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.
Follow us on:
For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.
Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CEST | Press release
STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: email@example.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: firstname.lastname@example.org TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen
Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CEST | Pressmeddelande
STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: email@example.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: firstname.lastname@example.org TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p
Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CEST | Pressmeddelande
STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva
Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CEST | Press release
STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre
Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CEST | Pressmeddelande
Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201
Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CEST | Press release
Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom